EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain
Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to thepatient and society. However, current data on IBD incidence and burden are limitedbecause of the paucity of nationwide epidemiological studies, heterogeneous designs, anda low number of participating centers a...
Gespeichert in:
Veröffentlicht in: | Therapeutic advances in gastroenterology 2019-01, Vol.12 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | Therapeutic advances in gastroenterology |
container_volume | 12 |
creator | Chaparro María Barreiro-de Acosta Manuel Benítez, José Manuel Cabriada, José Luis Casanova, María José Ceballos, Daniel Esteve María Fernández Hipólito Ginard, Daniel Gomollón Fernando Lorente Rufo Nos Pilar Sabino, Riestra Rivero Montserrat Robledo, Pilar Rodríguez, Cristina Sicilia Beatriz Torrella Emilio Garre Ana García-Esquinas, Esther Rodríguez-Artalejo, Fernando Gisbert, Javier P Abraldes, A |
description | Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to thepatient and society. However, current data on IBD incidence and burden are limitedbecause of the paucity of nationwide epidemiological studies, heterogeneous designs, anda low number of participating centers and sample size. The EpidemIBD study is alarge-scale investigation to provide an accurate assessment of the incidence of IBD inSpain, as well as treatment patterns and outcomes.Methods:This multicenter, population-based incidence cohort study included patients aged>18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD)diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population.Each participating patient will attend 10 clinic visits during 5 years of follow up.Demographic data, IBD characteristics and family history, complications, treatments,surgeries, and hospital admissions will be recorded.Results:The EpidemIBD study is the first large-scale nationwide study to investigate theincidence of IBD in Spain. Enrollment is now completed and 3627 patients are currentlybeing followed up.Conclusions:The study has been designed to overcome many of the limitations of previous Europeanstudies into IBD incidence by prospectively recruiting a large number of patients fromall regions of Spain. In addition to epidemiological information about the burden ofIBD, the 5-year follow-up period will also provide information on treatment patterns,and the natural history and financial burden of IBD. |
doi_str_mv | 10.1177/1756284819847034 |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2331604332</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2331604332</sourcerecordid><originalsourceid>FETCH-proquest_journals_23316043323</originalsourceid><addsrcrecordid>eNqNjjtPxDAQhC0EEsejp1yJOmDHIc5RAoeghoLutOBNtCfHDt5E6P49CULUVDP6ZkYapS6MvjLGuWvjbuqyqRqzbiqnbXWgVgsqFnb45-3bsToR2Wldl86uVypsBvbUP9893ELGkVPEQIDRgyfhLkJqASFg7qiQjyWjnwGnkDqeAcg4-f1c49gG7HscU97De_qiAJ6FUAg4wsuAHM_UUYtB6PxXT9Xl4-b1_qkYcvqcSMbtLk15fiDb0lpT68ra0v6v9Q2YPU-G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331604332</pqid></control><display><type>article</type><title>EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain</title><source>DOAJ Directory of Open Access Journals</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Chaparro María ; Barreiro-de Acosta Manuel ; Benítez, José Manuel ; Cabriada, José Luis ; Casanova, María José ; Ceballos, Daniel ; Esteve María ; Fernández Hipólito ; Ginard, Daniel ; Gomollón Fernando ; Lorente Rufo ; Nos Pilar ; Sabino, Riestra ; Rivero Montserrat ; Robledo, Pilar ; Rodríguez, Cristina ; Sicilia Beatriz ; Torrella Emilio ; Garre Ana ; García-Esquinas, Esther ; Rodríguez-Artalejo, Fernando ; Gisbert, Javier P ; Abraldes, A</creator><creatorcontrib>Chaparro María ; Barreiro-de Acosta Manuel ; Benítez, José Manuel ; Cabriada, José Luis ; Casanova, María José ; Ceballos, Daniel ; Esteve María ; Fernández Hipólito ; Ginard, Daniel ; Gomollón Fernando ; Lorente Rufo ; Nos Pilar ; Sabino, Riestra ; Rivero Montserrat ; Robledo, Pilar ; Rodríguez, Cristina ; Sicilia Beatriz ; Torrella Emilio ; Garre Ana ; García-Esquinas, Esther ; Rodríguez-Artalejo, Fernando ; Gisbert, Javier P ; Abraldes, A</creatorcontrib><description>Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to thepatient and society. However, current data on IBD incidence and burden are limitedbecause of the paucity of nationwide epidemiological studies, heterogeneous designs, anda low number of participating centers and sample size. The EpidemIBD study is alarge-scale investigation to provide an accurate assessment of the incidence of IBD inSpain, as well as treatment patterns and outcomes.Methods:This multicenter, population-based incidence cohort study included patients aged>18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD)diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population.Each participating patient will attend 10 clinic visits during 5 years of follow up.Demographic data, IBD characteristics and family history, complications, treatments,surgeries, and hospital admissions will be recorded.Results:The EpidemIBD study is the first large-scale nationwide study to investigate theincidence of IBD in Spain. Enrollment is now completed and 3627 patients are currentlybeing followed up.Conclusions:The study has been designed to overcome many of the limitations of previous Europeanstudies into IBD incidence by prospectively recruiting a large number of patients fromall regions of Spain. In addition to epidemiological information about the burden ofIBD, the 5-year follow-up period will also provide information on treatment patterns,and the natural history and financial burden of IBD.</description><identifier>ISSN: 1756-283X</identifier><identifier>EISSN: 1756-2848</identifier><identifier>DOI: 10.1177/1756284819847034</identifier><language>eng</language><publisher>London: Sage Publications Ltd</publisher><subject>Design ; Gastroenterology ; Inflammatory bowel disease</subject><ispartof>Therapeutic advances in gastroenterology, 2019-01, Vol.12</ispartof><rights>The Author(s), 2019. This work is licensed under the Creative Commons Attribution – Non-Commercial License http://www.creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids></links><search><creatorcontrib>Chaparro María</creatorcontrib><creatorcontrib>Barreiro-de Acosta Manuel</creatorcontrib><creatorcontrib>Benítez, José Manuel</creatorcontrib><creatorcontrib>Cabriada, José Luis</creatorcontrib><creatorcontrib>Casanova, María José</creatorcontrib><creatorcontrib>Ceballos, Daniel</creatorcontrib><creatorcontrib>Esteve María</creatorcontrib><creatorcontrib>Fernández Hipólito</creatorcontrib><creatorcontrib>Ginard, Daniel</creatorcontrib><creatorcontrib>Gomollón Fernando</creatorcontrib><creatorcontrib>Lorente Rufo</creatorcontrib><creatorcontrib>Nos Pilar</creatorcontrib><creatorcontrib>Sabino, Riestra</creatorcontrib><creatorcontrib>Rivero Montserrat</creatorcontrib><creatorcontrib>Robledo, Pilar</creatorcontrib><creatorcontrib>Rodríguez, Cristina</creatorcontrib><creatorcontrib>Sicilia Beatriz</creatorcontrib><creatorcontrib>Torrella Emilio</creatorcontrib><creatorcontrib>Garre Ana</creatorcontrib><creatorcontrib>García-Esquinas, Esther</creatorcontrib><creatorcontrib>Rodríguez-Artalejo, Fernando</creatorcontrib><creatorcontrib>Gisbert, Javier P</creatorcontrib><creatorcontrib>Abraldes, A</creatorcontrib><title>EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain</title><title>Therapeutic advances in gastroenterology</title><description>Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to thepatient and society. However, current data on IBD incidence and burden are limitedbecause of the paucity of nationwide epidemiological studies, heterogeneous designs, anda low number of participating centers and sample size. The EpidemIBD study is alarge-scale investigation to provide an accurate assessment of the incidence of IBD inSpain, as well as treatment patterns and outcomes.Methods:This multicenter, population-based incidence cohort study included patients aged>18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD)diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population.Each participating patient will attend 10 clinic visits during 5 years of follow up.Demographic data, IBD characteristics and family history, complications, treatments,surgeries, and hospital admissions will be recorded.Results:The EpidemIBD study is the first large-scale nationwide study to investigate theincidence of IBD in Spain. Enrollment is now completed and 3627 patients are currentlybeing followed up.Conclusions:The study has been designed to overcome many of the limitations of previous Europeanstudies into IBD incidence by prospectively recruiting a large number of patients fromall regions of Spain. In addition to epidemiological information about the burden ofIBD, the 5-year follow-up period will also provide information on treatment patterns,and the natural history and financial burden of IBD.</description><subject>Design</subject><subject>Gastroenterology</subject><subject>Inflammatory bowel disease</subject><issn>1756-283X</issn><issn>1756-2848</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNjjtPxDAQhC0EEsejp1yJOmDHIc5RAoeghoLutOBNtCfHDt5E6P49CULUVDP6ZkYapS6MvjLGuWvjbuqyqRqzbiqnbXWgVgsqFnb45-3bsToR2Wldl86uVypsBvbUP9893ELGkVPEQIDRgyfhLkJqASFg7qiQjyWjnwGnkDqeAcg4-f1c49gG7HscU97De_qiAJ6FUAg4wsuAHM_UUYtB6PxXT9Xl4-b1_qkYcvqcSMbtLk15fiDb0lpT68ra0v6v9Q2YPU-G</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Chaparro María</creator><creator>Barreiro-de Acosta Manuel</creator><creator>Benítez, José Manuel</creator><creator>Cabriada, José Luis</creator><creator>Casanova, María José</creator><creator>Ceballos, Daniel</creator><creator>Esteve María</creator><creator>Fernández Hipólito</creator><creator>Ginard, Daniel</creator><creator>Gomollón Fernando</creator><creator>Lorente Rufo</creator><creator>Nos Pilar</creator><creator>Sabino, Riestra</creator><creator>Rivero Montserrat</creator><creator>Robledo, Pilar</creator><creator>Rodríguez, Cristina</creator><creator>Sicilia Beatriz</creator><creator>Torrella Emilio</creator><creator>Garre Ana</creator><creator>García-Esquinas, Esther</creator><creator>Rodríguez-Artalejo, Fernando</creator><creator>Gisbert, Javier P</creator><creator>Abraldes, A</creator><general>Sage Publications Ltd</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PKEHL</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20190101</creationdate><title>EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain</title><author>Chaparro María ; Barreiro-de Acosta Manuel ; Benítez, José Manuel ; Cabriada, José Luis ; Casanova, María José ; Ceballos, Daniel ; Esteve María ; Fernández Hipólito ; Ginard, Daniel ; Gomollón Fernando ; Lorente Rufo ; Nos Pilar ; Sabino, Riestra ; Rivero Montserrat ; Robledo, Pilar ; Rodríguez, Cristina ; Sicilia Beatriz ; Torrella Emilio ; Garre Ana ; García-Esquinas, Esther ; Rodríguez-Artalejo, Fernando ; Gisbert, Javier P ; Abraldes, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_23316043323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Design</topic><topic>Gastroenterology</topic><topic>Inflammatory bowel disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chaparro María</creatorcontrib><creatorcontrib>Barreiro-de Acosta Manuel</creatorcontrib><creatorcontrib>Benítez, José Manuel</creatorcontrib><creatorcontrib>Cabriada, José Luis</creatorcontrib><creatorcontrib>Casanova, María José</creatorcontrib><creatorcontrib>Ceballos, Daniel</creatorcontrib><creatorcontrib>Esteve María</creatorcontrib><creatorcontrib>Fernández Hipólito</creatorcontrib><creatorcontrib>Ginard, Daniel</creatorcontrib><creatorcontrib>Gomollón Fernando</creatorcontrib><creatorcontrib>Lorente Rufo</creatorcontrib><creatorcontrib>Nos Pilar</creatorcontrib><creatorcontrib>Sabino, Riestra</creatorcontrib><creatorcontrib>Rivero Montserrat</creatorcontrib><creatorcontrib>Robledo, Pilar</creatorcontrib><creatorcontrib>Rodríguez, Cristina</creatorcontrib><creatorcontrib>Sicilia Beatriz</creatorcontrib><creatorcontrib>Torrella Emilio</creatorcontrib><creatorcontrib>Garre Ana</creatorcontrib><creatorcontrib>García-Esquinas, Esther</creatorcontrib><creatorcontrib>Rodríguez-Artalejo, Fernando</creatorcontrib><creatorcontrib>Gisbert, Javier P</creatorcontrib><creatorcontrib>Abraldes, A</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Therapeutic advances in gastroenterology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chaparro María</au><au>Barreiro-de Acosta Manuel</au><au>Benítez, José Manuel</au><au>Cabriada, José Luis</au><au>Casanova, María José</au><au>Ceballos, Daniel</au><au>Esteve María</au><au>Fernández Hipólito</au><au>Ginard, Daniel</au><au>Gomollón Fernando</au><au>Lorente Rufo</au><au>Nos Pilar</au><au>Sabino, Riestra</au><au>Rivero Montserrat</au><au>Robledo, Pilar</au><au>Rodríguez, Cristina</au><au>Sicilia Beatriz</au><au>Torrella Emilio</au><au>Garre Ana</au><au>García-Esquinas, Esther</au><au>Rodríguez-Artalejo, Fernando</au><au>Gisbert, Javier P</au><au>Abraldes, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain</atitle><jtitle>Therapeutic advances in gastroenterology</jtitle><date>2019-01-01</date><risdate>2019</risdate><volume>12</volume><issn>1756-283X</issn><eissn>1756-2848</eissn><abstract>Background:Inflammatory bowel disease (IBD) is associated with a considerable burden to thepatient and society. However, current data on IBD incidence and burden are limitedbecause of the paucity of nationwide epidemiological studies, heterogeneous designs, anda low number of participating centers and sample size. The EpidemIBD study is alarge-scale investigation to provide an accurate assessment of the incidence of IBD inSpain, as well as treatment patterns and outcomes.Methods:This multicenter, population-based incidence cohort study included patients aged>18 years with IBD (Crohn’s disease, ulcerative colitis, or unclassified IBD)diagnosed during 2017 in 108 hospitals in Spain, covering 50% of the Spanish population.Each participating patient will attend 10 clinic visits during 5 years of follow up.Demographic data, IBD characteristics and family history, complications, treatments,surgeries, and hospital admissions will be recorded.Results:The EpidemIBD study is the first large-scale nationwide study to investigate theincidence of IBD in Spain. Enrollment is now completed and 3627 patients are currentlybeing followed up.Conclusions:The study has been designed to overcome many of the limitations of previous Europeanstudies into IBD incidence by prospectively recruiting a large number of patients fromall regions of Spain. In addition to epidemiological information about the burden ofIBD, the 5-year follow-up period will also provide information on treatment patterns,and the natural history and financial burden of IBD.</abstract><cop>London</cop><pub>Sage Publications Ltd</pub><doi>10.1177/1756284819847034</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1756-283X |
ispartof | Therapeutic advances in gastroenterology, 2019-01, Vol.12 |
issn | 1756-283X 1756-2848 |
language | eng |
recordid | cdi_proquest_journals_2331604332 |
source | DOAJ Directory of Open Access Journals; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
subjects | Design Gastroenterology Inflammatory bowel disease |
title | EpidemIBD: rationale and design of a large-scale epidemiological study ofinflammatory bowel disease in Spain |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T06%3A01%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EpidemIBD:%20rationale%20and%20design%20of%20a%20large-scale%20epidemiological%20study%20ofinflammatory%20bowel%20disease%20in%20Spain&rft.jtitle=Therapeutic%20advances%20in%20gastroenterology&rft.au=Chaparro%20Mar%C3%ADa&rft.date=2019-01-01&rft.volume=12&rft.issn=1756-283X&rft.eissn=1756-2848&rft_id=info:doi/10.1177/1756284819847034&rft_dat=%3Cproquest%3E2331604332%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331604332&rft_id=info:pmid/&rfr_iscdi=true |